Jia Luo, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the challenges faced in diagnosing and treating NUT carcinoma. The cancer is frequently misdiagnosed as a poorly differentiated or squamous cell thoracic cancer. As a result, multidisciplinary discussions and molecular profiling is crucial in diagnosis. Dr Luo emphasises that improved clinical recognition for NUT carcinoma can facilitate the development of more effective treatments. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.